Related Experiment Video
Updated: Aug 7, 2026

Determination of the Transport Rate of Xenobiotics and Nanomaterials Across the Placenta using the ex vivo Human Placental Perfusion Model
Published on: June 18, 2013
Pregnane X receptor: molecular basis for species differences in CYP3A induction by xenobiotics
1Division of Drug Delivery and Disposition, School of Pharmacy, University of North Carolina, CB# 7360, Beard Hall, , Chapel Hill, NC 27599-7360, USA.
Abstract:
Determining the molecular basis for the observed species differences in the xenobiotic-mediated induction of cytochrome 3A (CYP3A) gene expression has become one of the biggest dilemmas of the modern era in toxicology. Recently, a novel orphan nuclear receptor, termed pregnane X receptor (PXR), has been implicated to play a key role in the regulation of CYP3A genes by xenobiotics. PXR is capable of binding to and activating transcription from specific response elements found in the CYP3A gene promoter from multiple species. Notably, compounds that are known to induce CYP3A selectively in human, mouse, rat, or rabbit also activate the corresponding PXR. Pregnenolone 16alpha-carbonitrile, a known CYP3A inducer in rodents, is a very efficacious activator of mouse and rat PXR, whereas rifampicin, a known inducer of CYP3A in humans and rabbits, is a very efficacious activator of human and rabbit PXR. Likewise, selective activators of PXR also induce CYP3A gene expression in the corresponding species. Orthologous receptors from human, mouse, rat, and rabbit have been cloned and characterized and share approx. 95% identity in their DNA binding domains. By contrast, they share only 75-80% identity in their amino acid sequences in the ligand-binding domain. Together, these data suggest that PXR is a critical regulator of CYP3A gene expression and activation of PXR is predictive of CYP3A induction. Furthermore, sequence differences in the ligand-binding domain, and not the DNA binding domain, appear to serve as the molecular basis for the species differences in CYP3A induction observed in vivo.
Insights
Species differences in cytochrome 3A (CYP3A) gene induction by xenobiotics are explained by the pregnane X receptor (PXR). Differences in PXR's ligand-binding domain dictate species-specific responses, impacting drug metabolism and toxicology.
Area of Science:
- Toxicology
- Molecular Biology
- Pharmacology
Background:
- Species-specific induction of cytochrome 3A (CYP3A) genes by xenobiotics presents a significant challenge in toxicology.
- The pregnane X receptor (PXR) has emerged as a key regulator of CYP3A gene expression in response to xenobiotics.
Purpose of the Study:
- To determine the molecular basis for species differences in xenobiotic-mediated CYP3A induction.
- To investigate the role of the pregnane X receptor (PXR) in mediating these species-specific responses.
Main Methods:
- Cloning and characterization of orthologous PXR receptors from human, mouse, rat, and rabbit.
- Assessing the ability of known CYP3A inducers to activate corresponding PXR orthologs.
- Comparing sequence identity in the DNA-binding and ligand-binding domains of PXR orthologs.
Main Results:
- Compounds inducing CYP3A in specific species also activated the corresponding PXR orthologs.
- Selective PXR activators induced CYP3A gene expression in a species-specific manner.
- High sequence identity (approx. 95%) was observed in the DNA-binding domains, while lower identity (75-80%) was found in the ligand-binding domains of PXR orthologs.
Conclusions:
- The pregnane X receptor (PXR) is a critical regulator of CYP3A gene expression, and PXR activation predicts CYP3A induction.
- Sequence variations within the ligand-binding domain of PXR are the primary molecular basis for observed species differences in CYP3A induction.
- Understanding PXR's role is crucial for predicting drug metabolism and potential toxicity across species.
More Related Videos
10:51Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
Published on: November 16, 2013
10:44Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
Related Concept Videos
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Metabolism: Overview
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Drug toxicity: Idiosyncratic Reactions